Introduction
This review discusses the recent literature on Kawasaki disease and focuses on the latest data concerning the disease etiology and pathogenesis, therapy in aggressive cases, and new tools in detecting and monitoring cardiac alterations. It also emphasizes the proposal of including altered laboratory values in revised diagnostic criteria aimed at identifying patients with incomplete disease.
Kawasaki disease, the leading cause of acquired heart disease in children in developing countries [1 ,2 ] , is now reported as a potential risk factor for adult ischemic heart disease and sudden death in early adulthood [3 , [4] [5] [6] .
Epidemiology
Kawasaki disease is most highly expressed among Asian populations, mainly Japanese [1 ,2 ,7] . In Hawaii, where most people are of Asian ancestry, the incidence is lower than in Japan, supporting the assumption that both genetic predisposition and environmental factors are important. Siblings of patients with Kawasaki disease have a significantly greater chance of acquiring the disease than children in the general population. Furthermore, patients with parental Kawasaki disease are prone to developing a severe course and recurrence of the disease, and high incidence of coronary artery aneurysms (CAAs) [8] .
Etiology
Kawasaki disease etiology is still unknown. Numerous factors have been suggested but none has been shown to be the trigger of the disease [1 ,2 ,9] .
Adenovirus infection (ADV) resembles Kawasaki disease since it is characterized by prolonged fever, conjunctivitis, lymphoadenopathy, and mucous membrane changes. In contrast to other viral infections, erythrocyte sedimentation rate (ESR) and C-reactive protein (CRP) are typically elevated. The rapid test performed on nasal wash specimen allows a quick diagnosis of ADV, thus reducing overdiagnosis of Kawasaki disease [10 ] .
A novel human coronavirus, 'New Haven coronavirus' (NCo-NH) has been identified in respiratory secretions from a 6-month old infant with typical Kawasaki disease [11 ] . A study in specimens of respiratory secretions showed that eight (72.7%) out of 11 Kawasaki disease children tested positive for HCoV-NH by reversetranscriptase polymerase chain reaction in contrast to one (4.5%) of 22 controls.
Mycoplasma pneumonia has recently been reported in a 7-year-old boy with Kawasaki disease, raising the concern that the differential diagnosis between Kawasaki disease and other febrile illnesses is often a dilemma. Indeed, Mycoplasma infection is characterized by fever, rash, conjunctivitis, and lymphoadenopathy [12] .
Data have shown a possible link between Kawasaki disease and pollen release [13 ] . In several Japanese regions, pollen-related symptoms in children significantly increased over time, as did the number of children with Kawasaki disease. The author advises, therefore, that babies prone to allergies may be susceptible to Kawasaki disease, thus providing a basis for a new causal agent.
Pathology
Organ inflammation in addition to artery involvement has been documented in Kawasaki disease. Different proteinases resulted in elevation in the acute and subacute phase of the disease, weakening vessel walls, and thus playing a potential role in the generation of aneurysms.
A significant overproduction of different cytokines and activation of endothelial cells has been demonstrated, but intimate pathogenesis is still lacking.
The role of immunoglobulin A (IgA) response in Kawasaki disease suggests that a viral agent entering a respiratory tract causes an oligoclonal IgA response [14 ] . IgA-secreting plasma cells overcome CD8þ lymphocytes and macrophages in the inflammatory infiltrate of all tissues and vascular walls in patients with Kawasaki disease, thus taking part in the disease pathogenesis.
The role of T cells and the functional state of T helper type 1 (Th1)/T helper type 2 (Th2) in the pathophysiology of the disease is still controversial. The levels of mRNA expression of Th1/Th2 cytokines (interferon-g (IFN-g) and interleukin-4 (IL-4)) have been analyzed, along with Th1/Th2-inducing transcription factors (T-bet and GATA-3) known to play pivotal roles in Th1/Th2 development [15 ] . In the peripheral blood mononuclear cells of patients with Kawasaki disease, a significant decrease in IFN-g mRNA levels was detected when compared with patients with other febrile diseases or healthy controls. T-bet mRNA, IL-4, and GATA-3 mRNA were also significantly reduced in children with Kawasaki disease in comparison to controls, a further indication of the suppressed state of Th1 and Th2 function at the levels of transcriptional regulation. These data suggesting functional suppression of peripheral T cells and reduced production of Th1/Th2 cytokines are inconsistent with previous studies in which activation was reported.
To identify patients responding to intravenous immunoglobulin (IVIG) therapy, the serum level of S100A12 was measured, which is a calcium binding protein with proinflammatory properties, secreted by activated neutrophils which stimulate endothelial cells, macrophages, and lymphocytes through interaction with the multiligand receptor for advanced glycation end products (RAGEs) [16] . S100A12 interaction with the receptor triggers cellular activation resulting in the synthesis and secretion of proinflammatory mediators. S100A12 decreases significantly in response to IVIG while in nonresponders serum concentrations increase. Therefore, S100A12 serum level should be a marker in determining patient's response to IVIG.
Atypical and incomplete Kawasaki disease
The lack of development of Kawasaki disease in typical manifestations in several children demonstrates that clinical criteria are not accurate for diagnosis. Since symptoms evolve over the first 10 days of illness, and gradually resolve even in the absence of therapy, and since there is no specific and sensitive diagnostic test, the challenge for the clinician is to differentiate Kawasaki disease from other febrile diseases with a rash. Medical history, physical examination, and laboratory tests including high white blood cell count, ESR, CRP, low hemoglobin, sodium and albumin levels could help in the diagnosis of 
Infants and adults
In patients less than 3 months old, Kawasaki disease displays an atypical or incomplete course with persistence of inflammation leading to rapid and severe coronary damage [18, 19] . At this age clinicians often miss the diagnosis. For this reason, echocardiography is mandatory in all suspected cases. Also older children develop cardiac complications. In children aged 6 years or over, age was an independent risk factor for coronary sequelae [20] , suggesting close cardiac control is required in school-age children with suspected Kawasaki disease [21] [22] [23] [24] .
In adults Kawasaki disease is seldom observed and usually has an atypical onset [25] . Multiple CAAs were detected in a previously asymptomatic 36-year-old man [26] .
Coronary artery lesions
Coronary damage, including dilatation, aneurysms, and giant aneurysms, still develop in up to 5% of timely treated patients [1 ,2 ] .
In contrast to aneurysms (diameter of coronary lumen 4 mm) that may regress in size and resolve over time, giant aneurysms (diameter of coronary lumen 8 mm) rarely improve, and often become stenotic leading to myocardial ischemia even in early adulthood [27 ] . Giant aneurysms, a potential risk either for rupture in the acute phase or later thrombosis due to stasis of blood flow and the procoagulant endothelial surface of vessels, are a major concern in Kawasaki disease and raise the problem of anticoagulation therapy in children, especially in infants [27 ] .
Coronary arterial lesions may develop progressive intimal hyperplasia even many years after Kawasaki disease manifestation. What happens in children with apparently intact coronary arteries after Kawasaki disease is under debate. Possibly they develop significant intimal hyperplasia and are at risk of progressing to stenosis or atherosclerosis. An immunohistochemical study [28 ] performed on a Kawasaki disease child without CAAs who died of sudden infant death syndrome showed a slightly thick intima, disruption of the lamina interna, and signs of persistent inflammation, suggesting that even coronary arteries normal on ultrasound may be damaged.
Concerns have been raised that children with Kawasaki disease may be predisposed to premature atherosclerosis in adulthood. In a study by Cheung et al. [29 ] , 36 Kawasaki disease children with CAAs displayed an adverse cardiovascular risk profile (low HDL and apolipoprotein-A1 (apo-A1) but high apo-B1 levels and increased peripheral arterial stiffness) after resolution of acute inflammation when compared with 29 children with Kawasaki disease without CAAs and 36 controls.
There is evidence of increased arterial stiffness related to the severity of inflammation in acute Kawasaki disease. Mannose-binding lectin (MBL) gene mutation is associated with Kawasaki disease related CAAs and atherosclerosis in adults. Cheung et al. [30] hypothesized that MBL genotypes modulate arterial stiffness in children who had suffered from Kawasaki disease. Blood pressure, brachioradial arterial stiffness, fasting total cholesterol, serum MBL and MBL genotypes were studied in a cohort of Kawasaki disease children (42 with CAAs and 21 without coronary involvement), and the modulating effects of different MBL expression genotypes -highlevel versus intermediate and low-level -on arterial stiffness in the different groups, were assessed. MBL genotype seems to influence arterial stiffness, a cardiovascular risk factor of early atherosclerosis.
Therapy IVIG (2 g/kg) with aspirin (50-80-100 mg/kg) given within 10 days of fever onset is the current therapy in Kawasaki disease patients [1 ,2 , 14 ,31] . No specific guidelines are available for the management of refractory patients in whom the parameters of inflammation do not subside, and fever persists with the risk for coronary artery sequelae. While a second infusion of IVIG (2 g/kg) in addition to high-dose aspirin is strongly recommended in all children with persistent or recurrent fever, proposals are lacking about how to treat the small group (3-4%) still remaining febrile [1 ,2 ,14 ] . There are different therapeutic approaches: either a third dose of IVIG (2 g/kg) or corticosteroids may be given, although patients failing to respond to a second infusion of immunoglobulin seem to be refractory to a third dose [1 ,2 ,32 ,33,34] .
There is still reluctance to use corticosteroids in Kawasaki disease either as first-line treatment or as additional therapy in children nonresponders to a second IVIG cycle. In refractory Kawasaki disease, however, corticosteroids as 'rescue therapy', either oral or pulsed (methylprednisolone 30 mg/kg, one to three courses), may be an alternative and safe treatment [35] [36] [37] .
Other therapies (cyclophosphamide, cyclosporin and ulinastatin) have proved successful in hastening resolution of fever in aggressive Kawasaki disease recalcitrant to IVIG and corticosteroids, though limited to a small group of patients.
Infliximab (a monoclonal antibody against tumor necrosis factor a) has been successfully given to seven patients by Burns and Glode [2 ], to two patients by Freeman et al. [32 ] , and to one patient by Weiss et al. [33] , all refractory to IVIG and corticosteroids, and with severe coronary involvement. While Burns and Glode reported a prompt defervescence along with normalization of CAAs in three out of seven patients, and Weiss a dramatic improvement in systemic symptoms and CAAs, Freeman et al. observed restoration of normal body temperature after 8 days in one patient and a conflicting response in the other one.
Though US criteria suggest that Kawasaki disease cannot be diagnosed before day 5 from fever onset, the presence of all typical symptoms may argue for earlier diagnosis and brings up the question of when to start IVIG therapy.
A recent study from Japan [38] has focused on this concern, but it is still controversial whether immunoglobulin has greater efficacy in preventing cardiac sequelae when given on or before day 4 or on days 3-9. It is likely that early administration of IVIG may require additional infusions. Children treated before day 5 could have a different viral disease that did not respond to IVIG, thus requiring a supplementary infusion.
The duration of fever in patients treated early is shorter than in the usual group, and since fever duration correlates with higher risk of CAAs, a timely treatment should prevent cardiac complications. There is no evidence, however, that early treatment prevents coronary damage or results in a greater requirement for additional IVIG [38] .
Although treatment of cardiovascular complications needs further definition, the prevention of thrombosis and stenosis following myointimal proliferation is the main concern. Up to now, low-dose aspirin (3-5 mg/ kg/day) has proven to be effective in children with small to medium-sized aneurysms, and there are only anecdotal reports of the association between aspirin and other antiplatelet agents (e.g. clopidrogel) [1 ,2 ].
Although long-term oral anticoagulation with warfarin is recommended in children with giant aneurysms secondary to Kawasaki disease, its efficacy and safety have not yet been proven. A cohort of 997 children with Kawasaki disease (37 with giant aneurysms, 33 without giant aneurysms) has been studied to determine if oral anticoagulation might prevent myocardial ischemia [28 ] . Patients were divided into a group given warfarin and a group of controls. At 12-month follow-up the authors concluded that warfarin does not protect against ischemia or influence the regression of aneurysms. Conversely, the potential benefit, the risk of bleeding and the difficulty in monitoring the international normalized ratio in children given long-term warfarin therapy are indications for a further large study before inclusion of the oral anticoagulation in the guidelines for giant aneurysm treatment.
Vaccinations
Live viral vaccines are an additional concern when children have Kawasaki disease since IVIG therapy blocks an active immune response. Whereas an interval of 6-11 months is recommended in Japan and the USA, there is no agreement with regard to the nonresponders who had received a second IVIG pulse. Miura et al. [39 ] suggest 9 months to be the optimal time interval for measles vaccination and possibly for mumps, rubella, and varicella viruses in re-treated children. The gap may be reduced if there is a risk of virus exposure, since passive immunization is not fully protective.
Cardiac imaging
Even though echocardiography remains the gold standard in the cardiac assessment of children with Kawasaki disease, and in detecting CAAs of proximal right and left coronary arteries, more invasive methods are required for better investigation of the entire coronary artery system. Complications of CAAs are not uncommon and require close monitoring as they may evolve into thrombosis, stenosis or rupture [40] [41] [42] .
Coronary magnetic resonance angiography (MRA) has proven to be equivalent to X-ray coronary angiography (XCA) and successful in the identification of CAAs as well as of great value for monitoring aneurysm progress [43 ] . MRA evaluation of blood flow should provide functional information about the flow in dilated arteries, thus addressing the question of appropriate anticoagulant therapy.
Electron beam computed tomography (EBT) is a noninvasive tool used in estimating myocardial characteristics. EBT enables the early detection of myocardial ischemia progressing from the endocardial to the central and epicardial region, thus allowing a prompt therapeutic approach [44] .
Multislice spiral computed tomography (MSCT) has proved to be a noninvasive sensitive tool comparable to coronary angiography in visualizing coronary artery stenosis in children with Kawasaki disease. In the future, MSCT could become the standard diagnostic tool replacing angiography in all patients with CAAs [45] .
Conclusion
Five percent of children with Kawasaki disease are still at risk for CAAs despite timely IVIG therapy. Infants and school-age children displaying an incomplete or atypical disease are at higher risk because of the lack of awareness of occurrence of the disease at this age. IVIG remains the gold standard of treatment to prevent CAAs, though 10-15% of children require additional infusion and steroids or immunosuppressants, and eventually biological drugs.
Giant aneurysms with a potential risk either for rupture in the acute phase or later thrombosis are major concerns in Kawasaki disease and long-term oral anticoagulation may arise in children, especially in young infants.
Echocardiography is important in confirming the diagnosis and should be performed in all suspected cases. New noninvasive tools including MRA and MSCT are of great value for the follow-up of aneurysm progress and outcome.
It is hoped that there will be a change in the current diagnostic criteria, which do not apply in cases of incomplete disease. Until the trigger agent is identified, high ESR, CRP, low hemoglobin, albumin, and sodium levels, along with high unexplained fever, could help the clinician to make an early diagnosis, and thus avoid the risk of coronary aneurysms [46] .
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